Efficacy and safety of perindopril arginine + amlodipine in hypertension

Elliott et al., 2015 | J Am Soc Hypertens | Rct

Citation

Elliott William J, Whitmore Jennifer, ... Bakris George L. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015-Apr;9(4):266-74. doi:10.1016/j.jash.2015.01.012

Abstract

To study the efficacy and safety of a new combination of perindopril arginine and amlodipine besylate, 837 subjects were enrolled in a three-arm, prospective, 59-center, randomized clinical trial. For 42 days, subjects (average seated blood pressure [BP], 158 ± 12/101 ± 5 mm Hg; age, 52 ± 10 years; 52% male; 34% black; 20% diabetic) received amlodipine/perindopril arginine (10/14 mg/d), perindopril erbumine (16 mg/d), or amlodipine (10 mg/d). Goal BP was <140/90 or <130/80 mm Hg in diabetics, per JNC 7 guidelines. The combination showed the largest change in seated BP (-23.7/-15.7 vs. -13.7/-9.5 vs. -19.3/-13.2 mm Hg, respectively; P < .0001), the highest proportion at goal BP (51% vs. 26% vs. 37%; P < .0001), and a lower incidence of pedal edema and adverse events compared with amlodipine. No deaths or significant differences across groups in early discontinuation, serum potassium, or rates of total or serious adverse events or glomerular filtration, were observed.

Key Findings

No deaths or significant differences across groups in early discontinuation, serum potassium, or rates of total or serious adverse events or glomerular filtration, were observed.

Outcomes Measured

  • blood pressure

Population

Field Value
Population See abstract
Sample Size 837
Age Range See abstract
Condition blood pressure

MeSH Terms

  • Amlodipine
  • Antihypertensive Agents
  • Diabetes Mellitus
  • Double-Blind Method
  • Drug Therapy, Combination
  • Edema
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Hypertension
  • Male
  • Middle Aged
  • Perindopril
  • Potassium
  • Prospective Studies

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
  • Vertical: arginine-cardiovascular

Provenance


Source extracted via PubMed E-utilities API on 2026-04-09